
|Videos|December 22, 2014
Dr. Ueno on Liquid Biopsy
Author(s)Naoto Tada Ueno, MD, PhD, FACP
Naoto Tada Ueno, MD, PhD, FACP, from The University of Texas MD Anderson Cancer Center, discusses the advantages of liquid biopsy to detect and monitor tumor growth.
Advertisement
Naoto Tada Ueno, MD, PhD, FACP, from The University of Texas MD Anderson Cancer Center, discusses the advantages of liquid biopsy to detect and monitor tumor growth.
It is difficult to subject patients to multiple traditional biopsies due to the potential risks and burden of the patient, explains Ueno.
Liquid biopsies, which use circulating tumor cells (CTCs) and fragments of tumor DNA, provide a bigger picture of biological changes at the metastatic site, without using invasive techniques.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutant NSCLC After TKI Progression
2
FDA Approval Sought for Lirafugratinib in Second-Line, FGFR2-Altered Cholangiocarcinoma
3
2025 Data Across Gynecologic, Lung, and Hematologic Cancers Reshape Treatment Landscapes
4
Third NDA for Rivoceranib/Camrelizumab Is Resubmitted to FDA for Unresectable HCC
5


































